Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00296036
First received: February 23, 2006
Last updated: November 17, 2010
Last verified: January 2009
  Purpose

RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether giving pyridoxine with or without topical urea/lactic acid-based cream is more effective than topical urea/lactic acid-based cream alone or a placebo in preventing hand-foot syndrome.

PURPOSE: This randomized phase III trial is studying pyridoxine and topical urea/lactic acid-based cream to see how well they work compared with giving pyridoxine together with a placebo, giving topical urea/lactic acid-based cream together with a placebo, or giving two placebos in preventing hand-foot syndrome in patients who are receiving capecitabine for breast cancer or other cancer.


Condition Intervention Phase
Breast Cancer
Drug/Agent Toxicity by Tissue/Organ
Unspecified Adult Solid Tumor, Protocol Specific
Dietary Supplement: pyridoxine hydrochloride
Drug: urea/lactic acid-based topical cream
Other: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
Official Title: A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Percentage of patients with ≥ moderate hand and/or foot symptoms as assessed by patient daily diary vs physician [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of patients with ≥ mild hand and/or foot symptoms as assessed by patient daily diary vs physician [ Designated as safety issue: No ]
  • Percentage of patients with ≥ severe hand and/or foot symptoms as assessed by patient daily diary vs physician [ Designated as safety issue: No ]
  • Mean maximum score of hand and/or foot symptoms as assessed by patient daily diary vs physician [ Designated as safety issue: No ]

Estimated Enrollment: 132
Study Start Date: June 2006
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (closed to accrual as of 10/24/2007)
Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
Dietary Supplement: pyridoxine hydrochloride
Given orally
Drug: urea/lactic acid-based topical cream
Applied topically
Experimental: Arm II (closed to accrual as of 10/24/2007)
Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
Drug: urea/lactic acid-based topical cream
Applied topically
Other: placebo
Given orally or applied topically
Experimental: Arm III (closed to accrual as of 10/24/2007)
Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
Dietary Supplement: pyridoxine hydrochloride
Given orally
Other: placebo
Given orally or applied topically
Placebo Comparator: Arm IV (closed to accrual as of 10/24/2007)
Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
Other: placebo
Given orally or applied topically
Experimental: Arm V
Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
Drug: urea/lactic acid-based topical cream
Applied topically
Placebo Comparator: Arm VI
Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
Other: placebo
Given orally or applied topically

Detailed Description:

OBJECTIVES:

  • Determine whether the prophylactic use of a topical urea/lactic acid cream can decrease the incidence/severity of capecitabine-caused palmar-plantar erythrodysesthesia in patients receiving capecitabine for breast and/or other cancer.
  • Evaluate the potential toxicity of this cream.
  • Determine whether the prophylactic use of vitamin B6 can decrease the incidence and/or severity of capecitabine-caused palmar-plantar erythrodysesthesia.
  • Evaluate the potential toxicity of vitamin B6.
  • Determine whether the prophylactic use of a topical urea/lactic acid cream in combination with vitamin B6 can decrease the incidence and/or severity of capecitabine caused palmar-plantar erythrodysesthesia.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (< 50 years old vs 50-60 years old vs > 60 years old), sex, capecitabine dose level (2000 mg/day vs 2500 mg/day), cancer type (breast vs other), and mode of therapy (adjuvant [including neo-adjuvant] therapy vs metastatic disease). Patients are randomized to 1 of 6 treatment arms (treatment arms I-IV closed to accrual as of 10/24/007).

  • Arm I (closed to accrual as of 10/24/2007): Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
  • Arm II (closed to accrual as of 10/24/2007): Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
  • Arm III (closed to accrual as of 10/24/2007): Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
  • Arm IV (closed to accrual as of 10/24/2007):Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
  • Arm V: Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
  • Arm VI: Patients receive placebo cream applied to palms and soles twice daily on days 1-21.

In all arms, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 132 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed breast and/or other cancer
  • Undergoing first treatment with capecitabine as adjuvant (including neo-adjuvant) therapy OR for metastatic disease

    • Receiving a dose of capecitabine either 2,000 mg/day (1,000 mg twice daily) OR 2,500 mg/day for 14 days with 4 courses of therapy at 3 week (+/- 3 days) intervals
  • Hormone-receptor status not specified

PATIENT CHARACTERISTICS:

  • Male or female
  • Menopausal status not specified
  • No history of allergy to urea-containing cream
  • No pre-existing neuropathy ≥ grade 2
  • No other dermatologic condition, that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment

PRIOR CONCURRENT THERAPY:

  • No other concurrent agents that function to prevent palmar-plantar erythrodysesthesia caused by capecitabine or topical agents in the hands or feet for other indications (e.g., dryness)
  • No concurrent vitamin B6 > 50 mg/day
  • No concurrent or planned use of over-the-counter products that contain urea or lactic acid, including any of the following:

    • Aqua Care®
    • Medicated Calamine^® lotion (0.3%)
    • Coppertone^® Waterproof Ultra Protection Sunblock
    • Dr. Scholl's^® Smooth Touch deep moisturizing cream
    • Depicure^® So Smooth Cream
    • Dove^® Moisturizing Cream Wash
    • Cetaphil^ ®Moisturizing Cream
    • Vaseline Intensive Care ^ ® lotion
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00296036

  Show 231 Study Locations
Sponsors and Collaborators
North Central Cancer Treatment Group
Investigators
Study Chair: Charles L. Loprinzi, MD Mayo Clinic
Investigator: Jeffrey L. Berenberg, MD University of Hawaii Cancer Research Center
  More Information

Additional Information:
Publications:
Responsible Party: Charles L. Loprinzi, North Central Cancer Treatment Group
ClinicalTrials.gov Identifier: NCT00296036     History of Changes
Other Study ID Numbers: CDR0000464246, NCCTG-N05C5, ROCHE-NCCTG-N05C5
Study First Received: February 23, 2006
Last Updated: November 17, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
drug/agent toxicity by tissue/organ
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Keratolytic Agents
Pyridoxine
Vitamin B 6
Pyridoxal
Capecitabine
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 17, 2014